Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 7/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 6/20 | 0.33 |
| ▸ | IL1B | P01584 | 5/20 | 0.33 |
| ▸ | TYK2 | P29597 | 3/20 | 0.33 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.33 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.32 |
| ▸ | ELANE | P08246 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30498161 | 0.90 | HTR3A (0.37) | HTR3AP2RX7IL1BTYK2MAP4K1 | |
| SCHEMBL27199481 | 0.90 | HTR3A (0.37) | HTR3AP2RX7IL1BTYK2MAP4K1 | |
| SCHEMBL27199478 | 0.90 | HTR3A (0.37) | HTR3AP2RX7IL1BTYK2MAP4K1 | |
| Trifluoroacetic Acid SCHEMBL27199538 | 0.88 | DPP4 (0.33) | DPP4DPP7 | |
| SCHEMBL27199314 | 0.78 | KDM4C (0.36) | HTR3AP2RX7IL1BTYK2KDM4C | |
| SCHEMBL27199317 | 0.78 | KDM4C (0.36) | HTR3AP2RX7IL1BTYK2KDM4C | |
| SCHEMBL25752565 | 0.77 | DHODH (0.34) | HTR3A | |
| Hydrochloric Acid SCHEMBL27199321 | 0.74 | ALDH1A1 (0.36) | HTR3A | |
| SCHEMBL30895158 | 0.73 | P2RX7 (0.35) | HTR3AP2RX7IL1BTYK2KDM4C | |
| SCHEMBL30895094 | 0.73 | P2RX7 (0.35) | HTR3AP2RX7IL1BTYK2KDM4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118401516-A | TYK2 inhibitors, compositions and methods thereof | 凌科药业(杭州)有限公司 | 2024-07-26 | — | — | CN | disclosed |
| US-20240124448-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2024-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124448-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | TYK2, JAK2, JAK1 | HTR3A 3455/4885P2RX7 3505/4885IL1B 1911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.